• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Benefits, efficacy, cost-effectiveness and infectious complications in transplant patients desensitized with intravenous immunoglobulin and anti-CD20 therapy.

作者信息

Vo A A, Jordan S C

机构信息

Kidney Transplant, Cedars-Sinai Medical Center, Los Angeles, CA, USA.

出版信息

Clin Exp Immunol. 2014 Dec;178 Suppl 1(Suppl 1):48-51. doi: 10.1111/cei.12508.

DOI:10.1111/cei.12508
PMID:25546759
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4285488/
Abstract
摘要

相似文献

1
Benefits, efficacy, cost-effectiveness and infectious complications in transplant patients desensitized with intravenous immunoglobulin and anti-CD20 therapy.接受静脉注射免疫球蛋白和抗CD20治疗脱敏的移植患者的获益、疗效、成本效益及感染并发症
Clin Exp Immunol. 2014 Dec;178 Suppl 1(Suppl 1):48-51. doi: 10.1111/cei.12508.
2
Rituximab and intravenous immune globulin for desensitization during renal transplantation.利妥昔单抗和静脉注射免疫球蛋白用于肾移植脱敏治疗。
N Engl J Med. 2008 Jul 17;359(3):242-51. doi: 10.1056/NEJMoa0707894.
3
Analysis of anti-HLA antibodies in sensitized kidney transplant candidates subjected to desensitization with intravenous immunoglobulin and rituximab.分析在接受静脉免疫球蛋白和利妥昔单抗脱敏治疗的致敏性肾移植候选者中的抗 HLA 抗体。
Transplantation. 2013 Jul 27;96(2):182-90. doi: 10.1097/TP.0b013e3182962c84.
4
Combination of Total Lymphoid Irradiation, Low-Dose IVIG and ATG as Rescue Therapy for Highly Sensitized and Antibody-Mediated Rejection Renal Transplant Recipients.全淋巴照射、低剂量静脉注射免疫球蛋白和抗胸腺细胞球蛋白联合作为高敏和抗体介导排斥反应肾移植受者的挽救治疗
Clin Transpl. 2014:215-21.
5
Reducing antibody levels in patients undergoing transplantation.降低移植患者的抗体水平。
N Engl J Med. 2008 Jul 17;359(3):305-6. doi: 10.1056/NEJMe0804275.
6
Benefits of rituximab combined with intravenous immunoglobulin for desensitization in kidney transplant recipients.利妥昔单抗联合静脉免疫球蛋白在肾移植受者脱敏中的获益。
Transplantation. 2014 Aug 15;98(3):312-9. doi: 10.1097/TP.0000000000000064.
7
Kidney transplant in highly sensitized patients after desensitization with plasmapheresis and low-dose intravenous immunoglobulin.采用血浆置换和小剂量静脉注射免疫球蛋白脱敏后，为高敏患者进行肾移植。
Exp Clin Transplant. 2010 Jun;8(2):130-5.
8
Use of immunoglobulin (Ig) in peripheral neuropathies. Impact of Ig on remission rates: comparison of intravenous immunoglobulin and subcutaneous immunoglobulin.免疫球蛋白（Ig）在外周神经病变中的应用。Ig对缓解率的影响：静脉注射免疫球蛋白与皮下注射免疫球蛋白的比较。
Clin Exp Immunol. 2014 Dec;178 Suppl 1(Suppl 1):25-6. doi: 10.1111/cei.12499.
9
Factors Predicting Risk for Antibody-mediated Rejection and Graft Loss in Highly Human Leukocyte Antigen Sensitized Patients Transplanted After Desensitization.高度人白细胞抗原致敏患者脱敏后移植的抗体介导排斥反应和移植物丢失的预测因素。
Transplantation. 2015 Jul;99(7):1423-30. doi: 10.1097/TP.0000000000000525.
10
Efficacy, outcomes, and cost-effectiveness of desensitization using IVIG and rituximab.免疫球蛋白静脉注射和利妥昔单抗脱敏治疗的疗效、结果和成本效益。
Transplantation. 2013 Mar 27;95(6):852-8. doi: 10.1097/TP.0b013e3182802f88.

引用本文的文献

1
Pushing the Survival Bar Higher: Two Decades of Innovation in Lung Transplantation.提高生存几率：肺移植二十年创新历程
J Clin Med. 2024 Sep 18;13(18):5516. doi: 10.3390/jcm13185516.
2
Safety, immunogenicity, pharmacokinetics, and efficacy of degradation of anti-HLA antibodies by IdeS (imlifidase) in chronic kidney disease patients.IdeS（依地西酸酶）降解慢性肾脏病患者抗 HLA 抗体的安全性、免疫原性、药代动力学和疗效。
Am J Transplant. 2018 Nov;18(11):2752-2762. doi: 10.1111/ajt.14733. Epub 2018 Apr 17.
3
Desensitisation strategies in high-risk children before kidney transplantation.高风险儿童肾移植前脱敏策略。
Pediatr Nephrol. 2018 Dec;33(12):2239-2251. doi: 10.1007/s00467-017-3882-2. Epub 2018 Jan 13.
4
The Incremental Cost of Incompatible Living Donor Kidney Transplantation: A National Cohort Analysis.不兼容活体供肾移植的增量成本：一项全国队列分析。
Am J Transplant. 2017 Dec;17(12):3123-3130. doi: 10.1111/ajt.14392. Epub 2017 Jul 21.

本文引用的文献

1
Benefits of rituximab combined with intravenous immunoglobulin for desensitization in kidney transplant recipients.利妥昔单抗联合静脉免疫球蛋白在肾移植受者脱敏中的获益。
Transplantation. 2014 Aug 15;98(3):312-9. doi: 10.1097/TP.0000000000000064.
2
Regulatory B cells: an exciting target for future therapeutics in transplantation.调节性B细胞：移植领域未来治疗的一个令人兴奋的靶点。
Front Immunol. 2014 Jan 22;5:11. doi: 10.3389/fimmu.2014.00011. eCollection 2014.
3
Reduced T-dependent humoral immunity in CD20-deficient mice.CD20 缺陷型小鼠 T 依赖性体液免疫应答降低。
J Immunol. 2013 Sep 15;191(6):3112-8. doi: 10.4049/jimmunol.1202098. Epub 2013 Aug 21.
4
Analysis of anti-HLA antibodies in sensitized kidney transplant candidates subjected to desensitization with intravenous immunoglobulin and rituximab.分析在接受静脉免疫球蛋白和利妥昔单抗脱敏治疗的致敏性肾移植候选者中的抗 HLA 抗体。
Transplantation. 2013 Jul 27;96(2):182-90. doi: 10.1097/TP.0b013e3182962c84.
5
Cryptic B cell response to renal transplantation.肾移植后隐匿性 B 细胞反应。
Am J Transplant. 2013 Jul;13(7):1713-23. doi: 10.1111/ajt.12308. Epub 2013 Jun 10.
6
Efficacy, outcomes, and cost-effectiveness of desensitization using IVIG and rituximab.免疫球蛋白静脉注射和利妥昔单抗脱敏治疗的疗效、结果和成本效益。
Transplantation. 2013 Mar 27;95(6):852-8. doi: 10.1097/TP.0b013e3182802f88.
7
Rituximab prevents an anamnestic response in patients with cryptic sensitization to HLA.利妥昔单抗可预防 HLA 隐匿性致敏患者的回忆应答。
Transplantation. 2013 Mar 15;95(5):701-4. doi: 10.1097/TP.0b013e31827be3c1.
8
Rationale of anti-CD19 immunotherapy: an option to target autoreactive plasma cells in autoimmunity.抗 CD19 免疫疗法的原理：针对自身免疫中自身反应性浆细胞的一种选择。
Arthritis Res Ther. 2012;14 Suppl 5(Suppl 5):S1. doi: 10.1186/ar3909. Epub 2012 Nov 8.
9
Antibody-mediated vascular rejection of kidney allografts: a population-based study.抗体介导的肾移植血管排斥反应：一项基于人群的研究。
Lancet. 2013 Jan 26;381(9863):313-9. doi: 10.1016/S0140-6736(12)61265-3. Epub 2012 Nov 23.
10
Lack of effect in desensitization with intravenous immunoglobulin and rituximab in highly sensitized patients.在高度致敏患者中，静脉注射免疫球蛋白和利妥昔单抗的脱敏治疗无效。
Transplantation. 2012 Aug 27;94(4):345-51. doi: 10.1097/TP.0b013e3182590d2e.